Yesterday, before market open, Descartes reported its fourth quarter and fiscal 2014 results. For the year, the Waterloo-based company earned $9.6-million on revenue of $151.3-million, a topline that was up 19% over 2013. In the fourth quarter, Descartes earned $2.9-million on revenue of $40.3-million.
New Descartes CEO Ed Ryan characterized the quarter.
“Our strategy of focusing on recurring revenues, organic growth and complementary acquisitions continues to deliver consistent, predictable financial results,” he said. “In addition to growing fourth-quarter revenues by 19 per cent over the prior year, we also generated record quarterly adjusted EBITDA of $11.9-million. As we look ahead to fiscal 2015, we remain optimistic about Descartes’s future as we continue to see strong demand for our SaaS-based solutions that drive the largest collaborative logistics community in the world.”
Garcea says the fourth quarter numbers exceeded his expectations. He believes there are both short term and long term catalysts for the company. Short term, the Global Maxfin analyst believes recent acquisitions such as Compudata and Impatex will drive higher margin topline growth. Long term, he says an expanding geographic footprint is among the factors that will secure the company’s future.
In a research update to clients yesterday, Garcea maintained his STRONG BUY rating on Descartes, but increased his one-year target price to (C) $21.50) from his previous $20.00 target.
At press time, shares of Descartes on the TSX were up .5% to $15.58.
________________________________________________________________________________________________________________
RBC Dominion Securities analyst Paul Treiber raised his target price on Celestica (Celestica Stock Quote, Chart, News, Analysts, Financials NYSE:CLS)… [Read More]
Roth Capital Markets analyst Craig Irwin raised his 12-month price target on Tesla (Tesla Stock Quote, Chart, News, Analysts, Financials… [Read More]
Newhaven Asset Management CEO and portfolio manager Ryan Bushell said on BNN Bloomberg’s Market Call on Oct. 17 that Algonquin… [Read More]
Stifel analyst Justin Keywood maintained his “Buy” rating and C$9.00 target price on WELL Health Technologies (WELL Health Technologies Stock… [Read More]
Newhaven Asset Management CEO and portfolio manager Ryan Bushell said on BNN Bloomberg’s Market Call on Oct. 17 that BCE… [Read More]
ATB Capital Markets analyst Martin Toner initiated coverage of Zoomd Technologies (Zoomd Technologies Stock Quote, Chart, News, Analysts, Financials TSX:ZOMD)… [Read More]